Ph3 study of GOG-3104 with endometrial cancer
Phase III Clinical Trial
A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)